Lauri Moilanen
Lauri Moilanen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anna Morena. D'Alise
Nouscom SRL, Rome, Italy
14 shared publications - Elisa Micarelli
Nouscom SRL, Rome, Italy
14 shared publications - Elisa Scarselli
Nouscom SRL, Rome, Italy
14 shared publications - Jan Böhm
Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland
14 shared publications - Joni Panula
NEON-S Research Unit, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
14 shared publications - Jouni Härkönen
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
14 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
B2M-mutated tumors frequently harbor somatic MMR or genomic stability mutations. A, Pie chart showing the distribution of B2M mutations occurring alone or in combination with MMR (MSH3 and MSH6) or genomic stability (POLE and POLD1) mutations. B, Sunburst charts illustrating the hierarchical distribution of tumors within each group, stratified by B2M mutation status (mutant or wild-type) and the presence or absence of at least one MMR or genomic stability mutation. C, Mosaic plot showing the distribution of IHC results (Het, heterogeneous) stratified by B2M mutation status. D, Lollipop plot of B2M mutations in samples stratified by IHC status. The plot highlights the distribution and types of somatic mutations along the B2M protein in B2M-negative and B2M-positive cases. E, Box plot showing the allele frequency of B2M mutations grouped by B2M IHC. F, Pie chart showing the distribution of tumor stages in B2M-negative colorectal cancer and urothelial cancer. Early stage was defined as stage I for colorectal cancer and non-MI for urothelial cancer, whereas advanced stage was defined as stage II–III for colorectal cancer and MI for urothelial cancer. G, Pie donut chart illustrating the distribution of B2M IHC status (inner ring) and corresponding germline mutations (outer ring). CRC, colorectal cancer; UC, urothelial cancer; WT, wild type.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
B2M-mutated tumors frequently harbor somatic MMR or genomic stability mutations. A, Pie chart showing the distribution of B2M mutations occurring alone or in combination with MMR (MSH3 and MSH6) or genomic stability (POLE and POLD1) mutations. B, Sunburst charts illustrating the hierarchical distribution of tumors within each group, stratified by B2M mutation status (mutant or wild-type) and the presence or absence of at least one MMR or genomic stability mutation. C, Mosaic plot showing the distribution of IHC results (Het, heterogeneous) stratified by B2M mutation status. D, Lollipop plot of B2M mutations in samples stratified by IHC status. The plot highlights the distribution and types of somatic mutations along the B2M protein in B2M-negative and B2M-positive cases. E, Box plot showing the allele frequency of B2M mutations grouped by B2M IHC. F, Pie chart showing the distribution of tumor stages in B2M-negative colorectal cancer and urothelial cancer. Early stage was defined as stage I for colorectal cancer and non-MI for urothelial cancer, whereas advanced stage was defined as stage II–III for colorectal cancer and MI for urothelial cancer. G, Pie donut chart illustrating the distribution of B2M IHC status (inner ring) and corresponding germline mutations (outer ring). CRC, colorectal cancer; UC, urothelial cancer; WT, wild type.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
NOUS-209 FSMs lost, gained, and kept between paired tumors. A, Timeline plot illustrating the follow-up of patients. Filled dots indicate primary and metachronous colorectal cancer and urothelial cancer. Empty circles denote colorectal cancer for which a tumor sample is not available. Light blue lines indicate the time interval between two tumor occurrences. B, Box plot showing, for each patient, the number of NOUS-209 FSMs lost between the first and second tumor, those kept across both tumors, and those gained in the second tumor. C, Box plot showing, for each patient, the median length of NOUS-209 FSMs lost, kept, and gained. D, Bar plot showing for each patient the number of MHC-I–predicted binders (IC50 < 500 nmol/L) for lost, kept, and gained FSMs, with annotations for B2M IHC results below for primary (P) and metachronous (M) samples. E, Box plots showing, for each patient, the number of predicted epitopes of NOUS-209 FSM lost, kept, and gained. F, Heatmap showing the FSMs lost for each patient, for whom immune editing is hypothesized. FSMs present in the patient's sample are colored if lost or kept. G, Venn diagram showing the overlap of mutations across the three tumors from patient Pt8. H–J, Line plots for patient Pt8 showing the number of NOUS-209 FSM (H), their median length (I), and the number of predicted good binders (J) across the lost, kept, and gained categories. CRC, colorectal cancer; UC, urothelial cancer.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
NOUS-209 FSMs lost, gained, and kept between paired tumors. A, Timeline plot illustrating the follow-up of patients. Filled dots indicate primary and metachronous colorectal cancer and urothelial cancer. Empty circles denote colorectal cancer for which a tumor sample is not available. Light blue lines indicate the time interval between two tumor occurrences. B, Box plot showing, for each patient, the number of NOUS-209 FSMs lost between the first and second tumor, those kept across both tumors, and those gained in the second tumor. C, Box plot showing, for each patient, the median length of NOUS-209 FSMs lost, kept, and gained. D, Bar plot showing for each patient the number of MHC-I–predicted binders (IC50 < 500 nmol/L) for lost, kept, and gained FSMs, with annotations for B2M IHC results below for primary (P) and metachronous (M) samples. E, Box plots showing, for each patient, the number of predicted epitopes of NOUS-209 FSM lost, kept, and gained. F, Heatmap showing the FSMs lost for each patient, for whom immune editing is hypothesized. FSMs present in the patient's sample are colored if lost or kept. G, Venn diagram showing the overlap of mutations across the three tumors from patient Pt8. H–J, Line plots for patient Pt8 showing the number of NOUS-209 FSM (H), their median length (I), and the number of predicted good binders (J) across the lost, kept, and gained categories. CRC, colorectal cancer; UC, urothelial cancer.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary table S1: FSPs with high-affinity binder predictions for HLA-A*03:01 and HLA-A*02:01 recurrently lost in at least 2 patients.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary table S1: FSPs with high-affinity binder predictions for HLA-A*03:01 and HLA-A*02:01 recurrently lost in at least 2 patients.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S1 shows the cumulative length of frameshift peptides and the estimated immunogenic potential across Lynch syndrome–associated cancers, separated by tumor type or by tumor chronology.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S1 shows the cumulative length of frameshift peptides and the estimated immunogenic potential across Lynch syndrome–associated cancers, separated by tumor type or by tumor chronology.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Lynch syndrome is characterized by the development of microsatellite-instable cancers that share neoantigens, offering an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine in clinical development, employing viral vectors encoding 209 shared neoantigen peptides derived from frameshift mutations (FSM) commonly found in microsatellite-instable tumors. In this study, we investigated the presence and dynamics of NOUS-209 targeted FSMs in both primary and metachronous Lynch syndrome–associated cancers. Whole-exome sequencing was performed for 73 tumors, including 58 colorectal cancers and 15 urothelial cancers, from 58 individuals with confirmed Lynch syndrome. A median of 57 FSMs per colorectal cancer and 24 FSMs per urothelial cancer were observed, with similar FSM burdens in both primary and metachronous tumors. Analysis of nine matched primary–metachronous tumor pairs revealed evidence of immune editing: FSMs predicted to encode highly immunogenic neoepitopes were selectively lost in metachronous tumors, whereas those with lower predicted immunogenicity were retained. Importantly, all subsequent primary cancers acquired novel FSMs encoding neoantigens with strong predicted HLA-binding affinity, supporting the rationale for NOUS-209–mediated immune interception. These findings demonstrated that NOUS-209 FSMs are present in both colorectal cancers and urothelial cancers in Lynch syndrome, expanding the therapeutic potential of NOUS-209 beyond colorectal cancer. Moreover, the emergence of novel targetable FSMs in metachronous tumors suggests that NOUS-209 immunotherapy may be effective in the prevention of both primary and metachronous Lynch syndrome–associated cancers.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Lynch syndrome is characterized by the development of microsatellite-instable cancers that share neoantigens, offering an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine in clinical development, employing viral vectors encoding 209 shared neoantigen peptides derived from frameshift mutations (FSM) commonly found in microsatellite-instable tumors. In this study, we investigated the presence and dynamics of NOUS-209 targeted FSMs in both primary and metachronous Lynch syndrome–associated cancers. Whole-exome sequencing was performed for 73 tumors, including 58 colorectal cancers and 15 urothelial cancers, from 58 individuals with confirmed Lynch syndrome. A median of 57 FSMs per colorectal cancer and 24 FSMs per urothelial cancer were observed, with similar FSM burdens in both primary and metachronous tumors. Analysis of nine matched primary–metachronous tumor pairs revealed evidence of immune editing: FSMs predicted to encode highly immunogenic neoepitopes were selectively lost in metachronous tumors, whereas those with lower predicted immunogenicity were retained. Importantly, all subsequent primary cancers acquired novel FSMs encoding neoantigens with strong predicted HLA-binding affinity, supporting the rationale for NOUS-209–mediated immune interception. These findings demonstrated that NOUS-209 FSMs are present in both colorectal cancers and urothelial cancers in Lynch syndrome, expanding the therapeutic potential of NOUS-209 beyond colorectal cancer. Moreover, the emergence of novel targetable FSMs in metachronous tumors suggests that NOUS-209 immunotherapy may be effective in the prevention of both primary and metachronous Lynch syndrome–associated cancers.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Lynch syndrome–associated cancers frequently carry additional alterations in MMR- and genomic stability–associated genes. A, Oncoplot showing the mutational landscape across tumors, classified into three groups based on cancer chronology. Genes are ordered by decreasing mutation frequency. Annotations include TMB (Mut/Mb), the number of NOUS-209 FSMs, and tumor type. In the TMB and NOUS-209 annotation bars, lighter shades indicate samples not confirmed as MSI. B and C, Boxplots depict the distribution of TMB and NOUS-209 FSM in samples without mutations and in those with at least one mutation in POLD1, POLE, MSH3, and MSH6 genes. D and E, Mosaic plot showing the distribution of tumor stage for colorectal cancer and muscle invasion for urothelial cancer, stratified by the presence (at least one mutation) or absence of mutations of no mutation or at least one mutation in POLE, POLD1, MSH3, or MSH6 genes. CRC, colorectal cancer; UC, urothelial cancer.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Lynch syndrome–associated cancers frequently carry additional alterations in MMR- and genomic stability–associated genes. A, Oncoplot showing the mutational landscape across tumors, classified into three groups based on cancer chronology. Genes are ordered by decreasing mutation frequency. Annotations include TMB (Mut/Mb), the number of NOUS-209 FSMs, and tumor type. In the TMB and NOUS-209 annotation bars, lighter shades indicate samples not confirmed as MSI. B and C, Boxplots depict the distribution of TMB and NOUS-209 FSM in samples without mutations and in those with at least one mutation in POLD1, POLE, MSH3, and MSH6 genes. D and E, Mosaic plot showing the distribution of tumor stage for colorectal cancer and muscle invasion for urothelial cancer, stratified by the presence (at least one mutation) or absence of mutations of no mutation or at least one mutation in POLE, POLD1, MSH3, or MSH6 genes. CRC, colorectal cancer; UC, urothelial cancer.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S2 illustrates the mutational landscape of mismatch repair and genomic stability genes across tumors grouped by cancer chronology, including annotations for TMB, NOUS-209 FSMs, and tumor type.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S2 illustrates the mutational landscape of mismatch repair and genomic stability genes across tumors grouped by cancer chronology, including annotations for TMB, NOUS-209 FSMs, and tumor type.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S5 shows the number and distribution of predicted MHC-II binders among lost, kept, and gained NOUS-209–derived epitopes across patients.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S5 shows the number and distribution of predicted MHC-II binders among lost, kept, and gained NOUS-209–derived epitopes across patients.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S3 shows correlations between CD8+ T cell infiltration (in tumor core and invasive margin) and both tumor mutational burden and NOUS-209 FSMs
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S3 shows correlations between CD8+ T cell infiltration (in tumor core and invasive margin) and both tumor mutational burden and NOUS-209 FSMs
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S4 shows the immune-driven evolution of tumor FSP profiles in Lynch syndrome–associated cancers, highlighting FSPs that are lost, maintained, or newly gained under T cell surveillance.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Supplementary Figure S4 shows the immune-driven evolution of tumor FSP profiles in Lynch syndrome–associated cancers, highlighting FSPs that are lost, maintained, or newly gained under T cell surveillance.